Deep vein thrombosis in upper extremities: Clinical characteristics, management strategies and long-term outcomes from the COMMAND VTE Registry.

[1]  S. Demeter,et al.  Upper Extremity Thrombosis: Etiology and Prognosis , 1982, Angiology.

[2]  T. Minas,et al.  Consequences of "conservative" conventional management of axillary vein thrombosis. , 1987, Canadian journal of surgery. Journal canadien de chirurgie.

[3]  R. Goldberg,et al.  Upper extremity deep vein thrombosis: a community-based perspective. , 2007, The American journal of medicine.

[4]  M. Monreal,et al.  Comparisons Between Upper and Lower Extremity Deep Vein Thrombosis: A Review of the RIETE Registry , 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[5]  John A. Heit,et al.  The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.

[6]  W. L. Skinner,et al.  Groshong catheter-associated subclavian venous thrombosis. , 1993, The American journal of medicine.

[7]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[8]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[9]  D. Jiménez,et al.  Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs , 2012, Journal of thrombosis and haemostasis : JTH.

[10]  S. Braekkan,et al.  Epidemiology of cancer-associated venous thrombosis. , 2013, Blood.

[11]  Samuel Z Goldhaber,et al.  Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) , 1999, The Lancet.

[12]  M. Toyofuku,et al.  Influence of Baseline Platelet Count on Outcomes in Patients With Venous Thromboembolism (from the COMMAND VTE Registry). , 2018, The American journal of cardiology.

[13]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[14]  S. Eichinger,et al.  Comparison between idiopathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence , 2008, Journal of thrombosis and haemostasis : JTH.

[15]  M. Guil,et al.  Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. , 2008, Chest.

[16]  S. Goldhaber,et al.  Upper-extremity deep vein thrombosis. , 2002, Circulation.

[17]  C. Tromeur,et al.  Incidence of upper-extremity deep vein thrombosis in western France: a community-based study , 2018, Haematologica.

[18]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[19]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[20]  C. Mai,et al.  Upper-extremity deep venous thrombosis: a review. , 2011, The American journal of medicine.

[21]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[22]  E. A. Edwards,et al.  Natural History of Major Venous Thrombosis of the Upper Extremity , 1970 .

[23]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.